Novo Nordisk’s Oral Wegovy Clears EU Hurdle, Putting a Pricier Pill Against a Pricing Squeeze
Published on 07/16/2026 at 13:23 | Redaktion boerse-global.de
Novo Nordisk has secured European approval for the first oral GLP-1 weight?loss tablet, a milestone that hands the Danish drugmaker a fresh weapon in its battle against both needle?shy patients and mounting cost pressures. The European Commission on 15 July 2026 cleared a 25?milligram daily version of Wegovy (oral semaglutide) alongside a new 7.2?milligram single?dose injection for obesity, with a rollout across multiple EU member states slated for the second half of 2026.
Investors had already priced in much of the good news. The stock closed Wednesday at €44.10, up 3.11% on the week and 17.33% over the past month. By the time of writing it had edged slightly higher to €44.73, a 1.42% daily gain that leaves the shares 47.85% above the 52?week low of €30.25 but still 26.62% below the July 2025 peak of €60.95.
The approval makes the European Union the fifth region – after the United States, Britain, the UAE and Bahrain – to green?light the tablet. CEO Maziar Mike Doustdar said the oral formulation offers many patients a “simpler and more acceptable alternative” to injections. That argument resonates with an estimated 22% of overweight adults who avoid GLP?1 therapies solely because of injection anxiety.
Clinical data from the OASIS?4 study back the switch: patients on the daily pill lost an average 17% of their body weight, versus 3% on placebo, and roughly one in three shed at least 20%. The safety profile matched the established injectable form. In the US the oral Wegovy already commands 89% of new oral GLP?1 prescriptions, dwarfing Eli Lilly’s Foundayo at 11%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Yet the celebratory mood is tempered by a stark financial reality. The company has guided for a 13% decline in both profit and revenue – a drop Doustdar himself described as “painful” – driven largely by pricing pressure. A US “most?favoured?nation” agreement is expected to cut monthly Wegovy costs from $350 to $250. That forced discount is the biggest single drag on the outlook, even as Medicare’s expanded GLP?1 bridge programme, effective from 1 July 2026, has pushed the total number of Americans on these therapies to an estimated 40 million.
The stock has enjoyed a strong technical rebound, trading 10.78% above its 50?day moving average and 8.85% above the 200?day moving average. The relative strength index stood at 67.9 in the primary article and had climbed to 70.5 by the time of the second report, approaching the overbought threshold. That, combined with the double?digit month?to?date gain, suggests the approval may already be fully priced in, leaving the shares vulnerable to any earnings disappointment.
Competitive threats also loom long?term. Eli Lilly’s retatrutide has posted up to 28% weight loss in clinical trials, a figure that overshadows the 17% recorded by oral semaglutide. How quickly Novo can pivot to next?generation combinations, notably CagriSema, will determine whether it can defend its market leadership against an increasingly aggressive rival.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
For now the immediate catalyst is the European rollout. The first prescription numbers from major markets – expected in the second half of 2026 – will reveal whether the oral format can replicate its US success. In the background, a DKK 15 billion share buyback programme signals management’s confidence in the stock’s value, but it is the execution of the tablet launch, not the repurchase, that will decide whether the current rally has further to run.
Ad
Novo Nordisk Stock: New Analysis - 16 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
